Findings of Research Misconduct, 44171-44172 [2014-17889]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 146 / Wednesday, July 30, 2014 / Notices
Filing Party: Joshua Stein, Esq.; Cozen
O’Connor; 1627 I Street NW., Suite
1100; Washington, DC 20006.
Synopsis: The agreement would
authorize the parties to charter space to
each other in the trades between ports
in Spain, Belgium, and Germany, on the
one hand, and ports on the U.S. East
and Gulf Coasts, on the other hand.
Agreement No.: 012289.
Title: Hanjin Shipping—Evergreen
Line Slot Charter Agreement.
Parties: Hanjin Shipping Co., Ltd. and
Evergreen Line Joint Service Agreement.
Filing Party: Paul M. Keane, Esq.;
Cichanowicz, Callan, Keane, Vengrow &
Textor, LLP; 61 Broadway, Suite 3000,
New York, NY 10006–2802.
Synopsis: The agreement authorizes
Hanjin to charter slots to Evergreen in
the trade between Japan and the U.S.
West Coast.
By Order of the Federal Maritime
Commission.
Dated: July 25, 2014.
Karen V. Gregory,
Secretary.
[FR Doc. 2014–17939 Filed 7–29–14; 8:45 am]
BILLING CODE 6730–01–P
FEDERAL RESERVE SYSTEM
mstockstill on DSK4VPTVN1PROD with NOTICES
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than August
14, 2014.
A. Federal Reserve Bank of Atlanta
(Chapelle Davis, Assistant Vice
President) 1000 Peachtree Street NE.,
Atlanta, Georgia 30309:
1. J. C. Jones, Jr.; Carole Jones; Patrick
C. Jones, all of Blackshear, Georgia; J. C.
Jones, III; 2012 Patrick C. Jones
Irrevocable Trust; JCJ Irrevocable Trust;
and The Jones Company, all of
Waycross, Georgia; to retain voting
shares of Jones Bancshares LP, and
VerDate Mar<15>2010
16:48 Jul 29, 2014
Jkt 232001
44171
thereby indirectly retain voting shares of
PrimeSouth Bancshares, both in
Waycross, Georgia, and PrimeSouth
Bank, Blackshear, Georgia.
Board of Governors of the Federal Reserve
System, July 25, 2014.
Margaret McCloskey Shanks,
Deputy Secretary of the Board.
Board of Governors of the Federal Reserve
System, July 25, 2014.
Margaret McCloskey Shanks,
Deputy Secretary of the Board.
[FR Doc. 2014–17907 Filed 7–29–14; 8:45 am]
[FR Doc. 2014–17906 Filed 7–29–14; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 6210–01–P
BILLING CODE 6210–01–P
Findings of Research Misconduct
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than August 25,
2014.
A. Federal Reserve Bank of Dallas (E.
Ann Worthy, Vice President) 2200
North Pearl Street, Dallas, Texas 75201–
2272:
1. First Bank Lubbock Bancshares,
Inc., Lubbock, Texas; to acquire 100
percent of the voting shares of Texas
Savings Bank, SSB, Snyder, Texas.
2. Red River Bancorp, Inc.,
Gainesville, Texas; to merge with
Chisholm Bancshares, Inc., and thereby
indirectly acquire North Texas Bank,
N.A., both in Decatur, Texas.
PO 00000
Frm 00020
Fmt 4703
Sfmt 4703
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Zhihua Zou, Ph.D., Harvard Medical
School and Fred Hutchinson Cancer
Research Center: Based on the reports of
investigations conducted by Harvard
Medical School (HMS) and Fred
Hutchinson Cancer Research Center
(FHCRC) and additional analysis
conducted by ORI in its oversight
review, ORI found that Dr. Zhihua Zou,
former Postdoctoral Fellow, Department
of Neurobiology, HMS, and former Staff
Scientist, Division of Basic Sciences,
FHCRC, engaged in research misconduct
in research supported by National
Institute of Dental and Craniofacial
Research (NIDCR), National Institutes of
Health (NIH), grants R01 DC001622 and
R01 DC004842.
ORI found that Respondent engaged
in research misconduct by falsifying
data that were included in two (2)
publications:
1. Zou, Z., Horowitz, L.F., Montmayeur,
J.P., Snapper, S., & Buck, L.B.
‘‘Genetic tracing reveals a
stereotyped sensory map in the
olfactory cortex.’’ Nature 414:173–
179, 2001 (hereafter referred to as
‘‘Nature 2001’’).
2. Zou, Z., Li, F., & Buck, L.B. ‘‘Odor
maps in the olfactory cortex.’’ Proc
Natl Acad Sci USA 102:7724–7729,
2005 (hereafter referred to as
‘‘PNAS 2005’’).
As a result of the investigations, both
publications have been retracted.
Specifically, ORI finds that
Respondent:
• Falsified Figures 2k, 2l, 3a, 3f, 3h,
and 3i in Nature 2001 and Figure 5C(b)
in PNAS 2005 by manipulating the
images to alter the number and location
of positively stained cells in the
olfactory bulb and olfactory cortex of
mice.
Dr. Zou has entered into a Voluntary
Settlement Agreement (Agreement) and
has voluntarily agreed for a period of
SUMMARY:
E:\FR\FM\30JYN1.SGM
30JYN1
44172
Federal Register / Vol. 79, No. 146 / Wednesday, July 30, 2014 / Notices
three (3) years, beginning on July 9,
2014:
(1) That the administrative actions
delineated in (2)–(4) below will be
required for three (3) years after the
effective date of the Agreement,
beginning on the date of Respondent’s
employment in a research position in
which he receives or applies for U.S.
Public Health Service (PHS) support;
however, if within three (3) years of the
effective date of the Agreement,
Respondent has not obtained
employment in a research position in
which he receives or applies for PHS
support, the administrative actions in
(2)–(4) will no longer apply;
(2) to have any PHS-supported
research supervised; Respondent agrees
that prior to the submission of an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of Respondent’s
duties is submitted to ORI for approval;
the supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research; Respondent
agrees that he shall not participate in
any PHS-supported research until such
a supervision plan is submitted to and
approved by ORI; Respondent agrees to
maintain responsibility for compliance
with the agreed upon supervision plan;
(3) that any institution employing him
shall submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(4) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
mstockstill on DSK4VPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453–
8800.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014–17889 Filed 7–29–14; 8:45 am]
BILLING CODE 4150–31–P
VerDate Mar<15>2010
16:48 Jul 29, 2014
Jkt 232001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
information collection project: ‘‘Care
Coordination Quality Measure for
Patients in the Primary Care Setting.’’ In
accordance with the Paperwork
Reduction Act, 44 U.S.C. 3501–3521,
AHRQ invites the public to comment on
this proposed information collection.
DATES: Comments on this notice must be
received by September 29, 2014.
ADDRESSES: Written comments should
be submitted to: Doris Lefkowitz,
Reports Clearance Officer, AHRQ, by
email at doris.lefkowitz@AHRQ.hhs.gov.
Copies of the proposed collection
plans, data collection instruments, and
specific details on the estimated burden
can be obtained from the AHRQ Reports
Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
email at doris.lefkowitz@AHRQ.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Proposed Project
Care Coordination Quality Measure for
Patients in the Primary Care Setting
Proposed Project
‘‘Care Coordination Measure
Development—Phase III’’
This project is Task Order #11 under
the Agency for Healthcare Research and
Quality (AHRQ) Prevention and Care
Management Technical Assistance
Center Indefinite Delivery Indefinite
Quantity contract. The project, entitled
‘‘Care Coordination Measure
Development—Phase III’’, will develop
a patient survey of the quality of care
coordination for adults in primary care
settings, i.e., the Care Coordination
Quality Measure for Primary Care
(CCQM–PC). The project will update the
Care Coordination Measures Atlas
(https://www.ahrq.gov/professionals/
systems/long-termcare/resources/
coordination/atlas/). In
combination with primary research, the
PO 00000
Frm 00021
Fmt 4703
Sfmt 4703
project will use the Atlas and prior work
that identified gaps in the measurement
of care coordination to develop and
pilot test a rigorous and
psychometrically sound patient
assessment (from the perspective of
patient and family) of the quality of care
coordination for adults within primary
care settings—the CCQM–PC. The
survey will address key care
coordination domains; be appropriate
for research; will set the stage for the
future development of measures for
quality reporting, accountability, and
payment purposes; and be consistent
with Consumer Assessment of
Healthcare Providers and Systems
(CAHPS®) principles. The instrument is
to be developed, cognitively tested,
revised and pilot tested. A stakeholder
panel will provide input throughout the
phases of the project.
There are four explicit objectives for
our analysis of the pilot-test data:
• Evaluate the quality of the
responses to the CCQM–PC survey
(through item functioning analysis).
• Determine how the items that ask
for reports of patient experiences could
be summarized into a smaller set of
composite measures (through factor
analysis).
• Evaluate the measurement
properties of the composite scales
(assessment of reliability, validity, and
variability of the measure).
• Identify information (i.e., case mix
adjusters) that should be used to adjust
scores to ensure valid comparisons
among primary care practices (PCPs).
• Determine how CCQM–PC scores
vary among practices that self-report
processes of care that are more or less
aligned with a medical home model.
This study is being conducted by
AHRQ through its contractor, American
Institutes for Research (AIR), pursuant
to AHRQ’s statutory authority to
conduct and support research on
healthcare and on systems for the
delivery of such care, including
activities with respect to quality
measurement and improvement. 42
U.S.C. 299a(a)(1) and (2).
Method of Collection
Thirty primary care practices of
different types and ownership
configurations will be recruited to
provide a patient sample to AHRQ’s
contractor, AIR for the purpose of
establishing the psychometrics of the
CCQM–PC and understanding the
relation of its domains to a practicelevel measure of processes of care, the
Medical Home Index (Long Version,
MHI–LV). The CCQM–PC will be
conducted by mail with phone followup for nonrespondents. Survey
E:\FR\FM\30JYN1.SGM
30JYN1
]]>Agencies
[Federal Register Volume 79, Number 146 (Wednesday, July 30, 2014)]
[Notices]
[Pages 44171-44172]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-17889]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Zhihua Zou, Ph.D., Harvard Medical School and Fred Hutchinson
Cancer Research Center: Based on the reports of investigations
conducted by Harvard Medical School (HMS) and Fred Hutchinson Cancer
Research Center (FHCRC) and additional analysis conducted by ORI in its
oversight review, ORI found that Dr. Zhihua Zou, former Postdoctoral
Fellow, Department of Neurobiology, HMS, and former Staff Scientist,
Division of Basic Sciences, FHCRC, engaged in research misconduct in
research supported by National Institute of Dental and Craniofacial
Research (NIDCR), National Institutes of Health (NIH), grants R01
DC001622 and R01 DC004842.
ORI found that Respondent engaged in research misconduct by
falsifying data that were included in two (2) publications:
1. Zou, Z., Horowitz, L.F., Montmayeur, J.P., Snapper, S., & Buck, L.B.
``Genetic tracing reveals a stereotyped sensory map in the olfactory
cortex.'' Nature 414:173-179, 2001 (hereafter referred to as ``Nature
2001'').
2. Zou, Z., Li, F., & Buck, L.B. ``Odor maps in the olfactory cortex.''
Proc Natl Acad Sci USA 102:7724-7729, 2005 (hereafter referred to as
``PNAS 2005'').
As a result of the investigations, both publications have been
retracted.
Specifically, ORI finds that Respondent:
Falsified Figures 2k, 2l, 3a, 3f, 3h, and 3i in Nature
2001 and Figure 5C(b) in PNAS 2005 by manipulating the images to alter
the number and location of positively stained cells in the olfactory
bulb and olfactory cortex of mice.
Dr. Zou has entered into a Voluntary Settlement Agreement
(Agreement) and has voluntarily agreed for a period of
[[Page 44172]]
three (3) years, beginning on July 9, 2014:
(1) That the administrative actions delineated in (2)-(4) below
will be required for three (3) years after the effective date of the
Agreement, beginning on the date of Respondent's employment in a
research position in which he receives or applies for U.S. Public
Health Service (PHS) support; however, if within three (3) years of the
effective date of the Agreement, Respondent has not obtained employment
in a research position in which he receives or applies for PHS support,
the administrative actions in (2)-(4) will no longer apply;
(2) to have any PHS-supported research supervised; Respondent
agrees that prior to the submission of an application for PHS support
for a research project on which the Respondent's participation is
proposed and prior to Respondent's participation in any capacity on
PHS-supported research, Respondent shall ensure that a plan for
supervision of Respondent's duties is submitted to ORI for approval;
the supervision plan must be designed to ensure the scientific
integrity of Respondent's research; Respondent agrees that he shall not
participate in any PHS-supported research until such a supervision plan
is submitted to and approved by ORI; Respondent agrees to maintain
responsibility for compliance with the agreed upon supervision plan;
(3) that any institution employing him shall submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract; and
(4) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8800.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014-17889 Filed 7-29-14; 8:45 am]
BILLING CODE 4150-31-P
